{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:01:41Z","timestamp":1769731301903,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.dld.2023.08.061","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T02:04:03Z","timestamp":1695348243000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-3846","authenticated-orcid":false,"given":"Fabio Salvatore","family":"Macaluso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"D'Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Fries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Viola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Ksissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Muscarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzio","family":"Belluardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Giangreco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Mocciaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Di Mitri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Ferracane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Vitello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Grova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Renna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Cas\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"De Vivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ventimiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2023.08.061_bib0001","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14712598.2017.1271871","article-title":"The biologics of ulcerative colitis","volume":"17","author":"Macaluso","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.dld.2023.08.061_bib0002","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.dld.2015.12.016","article-title":"Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease","volume":"48","author":"Armuzzi","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.08.061_bib0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.08.061_bib0004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/1389200221666200310111409","article-title":"JAK Inhibition as a therapeutic strategy for inflammatory bowel disease","volume":"21","author":"Macaluso","year":"2020","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dld.2023.08.061_bib0005","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2023.08.061_bib0006","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2023.08.061_bib0007","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/2050640619883566","article-title":"Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: a systematic overview of meta-analyses","volume":"7","author":"Pantavou","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.dld.2023.08.061_bib0008","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2022.01.127","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.08.061_bib0009","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.dld.2022.01.123","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology","volume":"54","author":"Bonovas","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.08.061_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2023.08.061_bib0011","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2023.08.061_bib0012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2021.04.018","article-title":"Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: a single-arm meta-analysis of observational studies","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.08.061_bib0013","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.08.061_bib0014","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1097\/MCG.0000000000001608","article-title":"Effectiveness and safety of tofacitinib for ulcerative colitis: systematic review and meta-analysis","volume":"56","author":"Taneja","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2023.08.061_bib0015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.061_bib0016","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2023.08.061_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"2003","journal-title":"Biometrika"},{"key":"10.1016\/j.dld.2023.08.061_bib0018","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.dld.2023.08.061_bib0019","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.15692","article-title":"Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease","volume":"51","author":"Piovani","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.08.061_bib0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cgh.2013.03.034","article-title":"Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30\u2009years of follow-up evaluation","volume":"12","author":"Kappelman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.061_bib0021","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.061_bib0022","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2023.08.061_bib0023","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.061_bib0024","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1572-0241.2001.03944.x","article-title":"Impact of cessation of smoking on the course of ulcerative colitis","volume":"96","author":"Beaugerie","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2023.08.061_bib0025","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/apt.17185","article-title":"Review article: guide to tofacitinib dosing in patients with ulcerative colitis","volume":"56","author":"Irving","year":"2022","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823009131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823009131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:24:17Z","timestamp":1761625457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823009131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1590865823009131"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.08.061","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.08.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}